RYR2 and catecholaminergic polymorphic ventricular tachycardia: The first CPVT iPSC-CM model from a patient carrying a RYR2 pathogenic variant (p.Phe2483Ile) was published in 2011 by Fatima et al. The analysis revealed more DAD events in patient iPSC-CMs compared to control iPSC-CMs and embryonal stem cell-derived cardiomyocytes (ESC-CM), recapitulating the CPVT phenotype.